<DOC>
	<DOC>NCT01003093</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety profile of an adjuvanted TB subunit vaccine administered at 0 and 2 months in healthy BCG-unvaccinated volunteers with no prior history of TB disease or known prior exposure to TB</brief_summary>
	<brief_title>A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis(TB) Subunit Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male Healthy based on medical examination/history at the inclusion Age between 18 and 55 years Signed informed consent Prepared to grant authorized persons access to the medical records The volunteer is likely to comply with instructions Known exposure to TB before (or expected during) the trial Prior BCG vaccination Granulomatous disease (by chest Xray, autoimmune screen) Vaccinated with live vaccine 3 months before first vaccination Administration of immune modulating drugs (steroids, immunosuppressive drugs or immunoglobulins) 3 months before the first vaccination HBV, HCV or HIV seropositive (HBsAg, HBsAb, HBc total and IgM ab and HCV, HIV1 and HIV2 ab) Participation in other clinical trials Positive Mantoux or QuantiFERONTB Gold Known hypersensitivity to any of the vaccine components Laboratory parameters outside of normal ranges considered clinically relevant</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Ag85B</keyword>
	<keyword>ESAT-6</keyword>
	<keyword>IC31</keyword>
</DOC>